Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Considerable evidence has accrued in the last two decades to support the hypothesis that alterations in serotonergic neuronal function in the central nervous system occur in patients with major depression.
-
The pharmacological inhibition of excitatory amino acid neurotransmission has evolved to be a major topic in neuropharmacology since enhanced synaptic action of glutamate and possibly other related neurotransmitters has been suggested to play a role both in acute neurological conditions such as ischemia and epilepsy and in chronic degenerative neurological diseases including Parkinson's disease, Huntington's disease and Alzheimer's disease.
-
Current palliative treatments are attempts to minimize the morbidity of abnormal behaviors and medical complications associated with dementia.
-
Thirty-one patients with Wilson's disease were evaluated with detailed neurologic and medical examinations.
-
Choline acetyltransferase (ChAT), acetylcholinesterase (AChE) and glutamic acid decarboxylase (GAD) activities were measured in 20 brain regions from autopsied control and senile dementia of the Alzheimer type (SDAT) cases.
-
Reductions in 2 neurotransmitter synthesizing enzymes in brain, glutamic acid decarboxylase (GAD) and choline acetyltransferase (CAT), have been found in dementias of different origins, including senile dementia (Alzheimer type).
-
SGLT2 inhibitors and GLP-1 receptor agonists have the greatest effect on cognition in T2DM, and the multi-component exercise as the most effective lifestyle component.
-
Cortisol is primarily synthesized by the adrenal glands, but also within specific tissues via a distinct enzymatic pathway. 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) catalyses the synthesis of cortisol within cells to create local higher cortisol environments in those organs where it is highly expressed such as the liver and brain.
-
16/100
Of 22,025,599 individuals screened, 2,051,275 were eligible; matched cohorts ranged from 10,113 to 857,773, with median follow-up of 4.7 to 7.2 years.
-
The observed protective effect may be explained by vascular and neuroprotective mechanisms unique to PDE5 inhibitors.
-
Alzheimer's Disease (AD), the most common neurodegenerative disease in the world, is caused by a variety of factors that lead to neuronal injury and an alteration in neurotransmitter production and release.
-
In older adults with HFpEF, finerenone conferred renal benefit without a detectable short-term cognitive signal.
-
We describe the demographic and clinical characteristics of new initiators of GLP-1RAs compared with initiators of alternative therapies, including sodium-glucose cotransporter-2 inhibitors (SGLT2i) and dipeptidyl peptidase-4 inhibitors (DPP-4i).
-
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is the leading cause of dementia in older people.
-
Alzheimer's disease (AD) is a progressive neurodegenerative condition marked by cognitive decline, memory loss, and cholinergic dysfunction [1].
-
Between 1979 and 2023, AD caused 2,430,795 deaths in U.S. adults.
-
Brexpiprazole was associated with a distinct neuropsychiatric adverse-event reporting pattern in Alzheimer’s disease compared with psychiatric indications, with the most consistent signals observed for delirium, falls, and agitation.
-
Rare confirmed initiation prevented a clinically interpretable admission-time strategy estimate.
-
Coumarins playing multiple roles in the life of plants also exhibit a wide range of positive effects for human health.
-
Sleep disturbance in Alzheimer’s disease (AD), particularly the reduction of slow wave sleep (SWS), has been proposed as a novel therapeutic target, with disease-modifying potential.
-
Apolipoprotein E4 (APOE4) is a major risk factor for Alzheimer’s disease (AD).
-
Forty-eight studies, mostly of weak- or moderate-quality, met inclusion criteria.
-
Cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) are central regulators of synaptic homeostasis, plasticity, and dysfunction during Alzheimer’s disease (AD) progression.
-
In this nationwide cohort, probucol use was associated with substantially lower dementia risk than statins, supporting evaluation of probucol for repurposing in dementia prevention.
-
16/100
Long-term metformin treatment is associated with a reduced risk of dementia and better memory performance among persons with pre-diabetes or T2D. Longer follow-up with more dementia cases is needed to confirm our findings.
From across this topic
10 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Association between exenatide use and incidence of Alzheimer's disease
- Economic evaluations during early (phase II) drug development: a role for clinical trial simulations?
- Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease
- Psychosis Management in Lewy Body Dementia: A Comprehensive Clinical Approach
- Protocol of a Phase II Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial of S-Adenosyl Methionine in Participants with Mild Cognitive Impairment or Dementia Due to Alzheimer's Disease
- Galantamine for Alzheimer's disease
- Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study
- Foresee Novel Targets for Alzheimer's Disease by Investigating Repurposed Drugs
- Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia
- Donanemab: The dawn of disease-modifying treatment for Alzheimer's disease in Australia